Latest Ipsen Stories

In the news release, Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen, issued 21-Aug-2012 by Inspiration Biopharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first subheadline should read "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up to a potential value of $215 million" rather than "Ipsen to pay Inspiration $30 million, with additional payments and investments totaling up...

CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of...

BOSTON, June 13, 2012 /PRNewswire/ -- Rhythm announced today that it has raised $25 million in a Series B financing round. All existing investors participated in the round--MPM Capital (MPM), New Enterprise Associates (NEA), and Third Rock Ventures (TRV)--as well as new investor, Ipsen (Euronext: IPN; ADR: IPSEY). The Series B financing brings the total capital raised by Rhythm to $65 million. Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for...

BARCELONA, Spain, December 14, 2011 /PRNewswire/ -- The Contract Research Organization Kymos Pharma Services -specialised in analysis for the pharmaceutical, fine chemicals, biotechnological, veterinary, cosmetic and nutraceuticals sectors- has signed an agreement with the French multinational group Ipsen to take in a team of eight scientists from Ipsen R&D Centre in Sant Feliu de Llobregat (Barcelona). For Kymos -with headquarters in Barcelona Science Park (PCB)...

LAGUNA NIGUEL, Calif., Oct. 3, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that the European Medicines Agency (EMA) has validated and accepted the filing of the Marketing Authorization Application (MAA) for Inspiration's IB1001, a recombinant factor IX (FIX) product for the treatment and prevention of bleeding in individuals with hemophilia B. In doing so, the EMA has verified that it will begin its regulatory review process of the MAA. The...

OSLO, Norway, September 27, 2011 /PRNewswire/ -- - Strategic collaboration with Ipsen for marketing rights in Europe and the rest of the world except Nordics and the US - Photocure to commercialise the product directly in the US market Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today the execution of a new commercial strategy for Hexvix, its...

ST. LOUIS, Dec. 6, 2010 /PRNewswire-FirstCall/ -- Monsanto Company (NYSE: MON) announced today the appointment of Laura K. Ipsen to the company's Board of Directors. Ipsen is currently the senior vice president and general manager, Connected Energy Industries, for Cisco, the worldwide leader in networking technology that transforms how people connect, communicate and collaborate, based in San Jose, Calif. Since joining the company in 1995, Ipsen founded and led Cisco's global policy and...

PARIS and LAUSANNE, Switzerland, February 4 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or...

NEW YORK, LONDON and HAMILTON, Bermuda, Jan. 21 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals ("Inspiration") to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio. Prior to this strategic partnership, Celtic Pharma held a direct interest in Inspiration's lead compound, IB1001 ("rFIX"), a new version of...

LAUSANNE, Switzerland and PARIS, October 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl(R)[1] (triptorelin embonate[2] 22.5 mg) successfully completed its European...